Axa
ONC

Axa’s BeOne Medicines Ltd ONC Stock Holding History

Axa’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35,910
Closed -$8.69M – 1070
2025
Q2 		$8.69M Buy
35,910
+2,245
+7% +$551K 0.03% 425
2025
Q1 		$9.16M Sell
33,665
-8,567
-20% -$2M 0.03% 398
2024
Q4 		$7.8M Sell
42,232
-11,281
-21% -$2.3M 0.02% 429
2024
Q3 		$12M Buy
53,513
+15
+0% +$2.7K 0.04% 362
2024
Q2 		$7.63M Buy
53,498
+31
+0.1% +$4.78K 0.02% 440
2024
Q1 		$8.36M Sell
53,467
-1,667
-3% -$268K 0.03% 444
2023
Q4 		$9.94M Sell
55,134
-1,291
-2% -$234K 0.03% 397
2023
Q3 		$10.1M Sell
56,425
-193
-0.3% -$38.2K 0.04% 392
2023
Q2 		$10.1M Buy
56,618
+36,139
+176% +$8.32M 0.03% 416
2023
Q1 		$4.41M Buy
20,479
+15,120
+282% +$3.63M 0.02% 594
2022
Q4 		$1.18M Sell
5,359
-23,337
-81% -$4.28M ﹤0.01% 859
2022
Q3 		$3.87M Buy
28,696
+183
+0.6% +$31.4K 0.02% 633
2022
Q2 		$4.61M Sell
28,513
-553
-2% -$86.4K 0.02% 600
2022
Q1 		$5.48M Buy
29,066
+298
+1% +$63.4K 0.02% 621
2021
Q4 		$7.79M Buy
28,768
+344
+1% +$116K 0.02% 554
2021
Q3 		$10.3M Sell
28,424
-13,266
-32% -$4.34M 0.03% 489
2021
Q2 		$14.3M Sell
41,690
-4,972
-11% -$1.65M 0.04% 435
2021
Q1 		$16.2M Buy
46,662
+109
+0.2% +$36.1K 0.05% 397
2020
Q4 		$12M Buy
46,553
+15,955
+52% +$4.39M 0.04% 463
2020
Q3 		$8.76M Buy
30,598
+2,758
+10% +$648K 0.03% 497
2020
Q2 		$5.25M Buy
27,840
+1,292
+5% +$210K 0.02% 601
2020
Q1 		$3.27M Sell
26,548
-2,047
-7% -$320K 0.02% 630
2019
Q4 		$4.74M Buy
28,595
+718
+3% +$119K 0.02% 631
2019
Q3 		$3.41M Sell
27,877
-40,769
-59% -$5.42M 0.01% 758
2019
Q2 		$8.51M Buy
68,646
+1,383
+2% +$176K 0.03% 513
2019
Q1 		$8.88M Buy
+67,263
New +$9.08M 0.03% 484

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Axa's ONC Position: Q3 2025 in Review

Axa sold out of BeOne Medicines Ltd (ONC) in Q3 2025, closing a stake of 35,910 shares — an estimated $8.69M sold.

Axa first reported a position in ONC in Q1 2019 and held it in 26 quarters. The position peaked at $16.2M in Q1 2021. 266 funds tracked by Wall St. Rank hold ONC as of Q3 2025.

  • Axa reported no remaining BeOne Medicines Ltd position as of Q3 2025 after selling out during the quarter.
  • Axa sold 35,910 BeOne Medicines Ltd shares in Q3 2025, an estimated $8.69M.
  • Axa first reported a position in BeOne Medicines Ltd in Q1 2019 and held it in 26 quarters.
  • Axa's BeOne Medicines Ltd position peaked at $16.2M in Q1 2021.
  • 266 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.